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Background: The neuropathology of patients with frontotemporal dementia (FTD) or
amyotrophic lateral sclerosis (ALS) due to a C9orf72 mutation is characterized by two
distinct types of characteristic protein depositions containing either TDP-43 or so-called
dipeptide repeat proteins that extend beyond frontal and temporal regions. Thalamus
and cerebellum seem to be preferentially affected by the dipeptide repeat pathology
unique to C9orf72 mutation carriers.
Objective: This study aimed to determine if mutation carriers showed an enhanced
degree of thalamic and cerebellar atrophy compared to sporadic patients or healthy
controls.
Methods: Atlas-based volumetry was performed in 13 affected C9orf72 FTD, ALS and
FTD/ALS patients, 45 sporadic FTD and FTD/ALS patients and 19 healthy controls.
Volumes and laterality indices showing significant differences between mutation carriers
and sporadic patients were subjected to binary logistic regression to determine the best
predictor of mutation carrier status.
Results: Compared to sporadic patients, mutation carriers showed a significant volume
reduction of the thalamus, which was most striking in the occipital, temporal and
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prefrontal subregion of the thalamus. Disease severity measured by mini mental status
examination (MMSE) and FTD modified Clinical Dementia Rating Scale Sum of Boxes
(FTD-CDR-SOB) significantly correlated with volume reduction in the aforementioned
thalamic subregions. No significant atrophy of cerebellar regions could be detected.
A logistic regression model using the volume of the prefrontal and the laterality index of
the occipital subregion of the thalamus as predictor variables resulted in an area under
the curve (AUC) of 0.88 while a model using overall thalamic volume still resulted in an
AUC of 0.82.
Conclusion: Our data show that thalamic atrophy in C9orf72 mutation carriers goes
beyond the expected atrophy in the prefrontal and temporal subregion and is in
good agreement with the cortical atrophy pattern described in C9orf72 mutation
carriers, indicating a retrograde degeneration of functionally connected regions. Clinical
relevance of the detected thalamic atrophy is illustrated by a correlation with disease
severity. Furthermore, the findings suggest MRI volumetry of the thalamus to be of
high predictive value in differentiating C9orf72 mutation carriers from patients with
sporadic FTD.
Keywords: C9orf72, frontotemporal dementia, amyotrophic lateral sclerosis, atlas based volumetric MRI analysis,
thalamus, cerebellum, salience network
INTRODUCTION
Frontotemporal dementia (FTD) and amyotrophic lateral
sclerosis (ALS) are heterogeneous neurodegenerative disorders
that are associated with one another in approximately 15% of
the cases (Lomen-Hoerth et al., 2002). FTD can present with
socially inappropriate behavior, apathy, lack of empathy, changes
in diet and compulsive behaviors. Compared to Alzheimer’s
disease there is typically a relative preservation of memory
and visuospatial function (Perry and Miller, 2013). ALS is
a motor neuron disease that is characterized by progressive
degeneration of upper and lower motor neurons. It typically
manifests with progressive muscle weakness, muscular atrophy,
spasticity and fasciculations (Lomen-Hoerth et al., 2002). The
most common known cause of familial FTD, familial ALS or
patients with a mixed presentation of both diseases (FTD/ALS)
is a hexanucleotide expansion mutation in a non-coding region
of C9orf72 (Cruts et al., 2013). Compared to sporadic patients
c9orf72 mutation carriers have a greater frequency of psychotic
symptoms like delusions, hallucinations or paranoid ideation and
show more severe memory impairment (Snowden et al., 2015).
Previous neuroimaging studies on c9orf72 mutation carriers
have shown relatively symmetrical atrophy most prominent in
the frontotemporal cortex and the insula, in keeping with the
atrophy pattern described in sporadic patients (Boxer et al.,
2011; Mahoney et al., 2012; Whitwell et al., 2012). In contrast
to sporadic patients, however, c9orf72 mutation carriers appear
Abbreviations: ALS, amyotrophic lateral sclerosis; AUC, area under the curve;
DPR, dipeptide repeat proteins; FTD, frontotemporal dementia; FTD-CDR-SOB,
FTD modified Clinical Dementia Rating Scale Sum of Boxes; HC, healthy controls;
LI, laterality index; LPBA40, LONI Probabilistic Atlas; MDN, mediodorsal nucleus;
MMSE, mini mental status examination; OTH, Oxford Thalamic Connectivity
Atlas; ROC, receiver operating characteristic; SN, salience network.
to have more parietal and occipital cortical atrophy creating a
more diffuse cortical atrophy pattern. Furthermore bithalamic
and cerebellar involvement have been described (Yokoyama
and Rosen, 2012; Bede et al., 2013; Prado et al., 2015; Floeter
et al., 2016). Moreover, volumetric imaging data from the
genetic frontotemporal dementia initiative (GenFI) show an
early affection of thalamus and cerebellum in C9orf72 mutation
carriers compared to healthy controls (HC) as well as to GRN and
MAPT mutation carriers (Rohrer et al., 2015).
A neuropathological hallmark of C9orf72 mutation carrier
status is the intracellular deposition of five dipeptide repeat
proteins (DPR). These proteins are a product of repeat-
associated non-ATG translation from sense and antisense
transcripts (Ash et al., 2013; Gendron et al., 2013; Mori et al.,
2013a,b). Most frequent dipeptide repeat pathology, particular
inclusions of poly (GP) or poly (GA) can be detected in
neocortex, hippocampus and cerebellum but dipeptide repeat
inclusions are also abundant in thalamus (Schludi et al.,
2015).
These recent neuropathological and neuroimaging findings
provide evidence for an underappreciated role of the cerebellum
and thalamus in the pathogenesis of FTD and ALS caused
by a repeat expansion in C9orf72 (Prado et al., 2015; Rohrer
et al., 2015; Schludi et al., 2015). We hypothesized that
thalamus and cerebellum show an enhanced degree of atrophy
in C9orf72 expansion carriers compared to sporadic patients
and that thalamic atrophy goes beyond the expected atrophy
in the prefrontal and temporal subregion of the thalamus in
C9orf72 mutation carriers. In the current study, we therefore
aimed to elucidate the regional brain atrophy focusing on
thalamic and cerebellar atrophy in C9orf72 mutation carriers
compared to patients with sporadic FTD or FTD/ALS and healthy
controls.
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MATERIALS AND METHODS
Ethics Statement
The study was performed according to the declaration of Helsinki
(1991). Ethical approval for conduction of the study has been
obtained at the coordinating site at the University of Ulm
and all participating centers of the German consortium for
frontotemporal lobar degeneration. Written informed consent
was obtained from every participant.
Subjects
A total of 77 participants from the cohort of the German
consortium for frontotemporal lobar degeneration (Otto et al.,
2011) were included in the study: 13 symptomatic C9orf72
mutation carriers (8 FTD, 2 ALS, 3 FTD/ALS), 45 with sporadic
FTD (Medford and Critchley, 2010) or FTD/ALS (Snowden et al.,
2015) in whom a pathological C9orf72 expansion, MAPT or
GRN mutation has been excluded and 19 healthy elderly control
subjects. Diagnosis was made according to current international
consensus criteria (Brooks et al., 2000; Rascovsky et al., 2011).
Demographic features of participants are listed in Table 1.
Participants underwent general cognitive screening using
the mini mental status examination (MMSE). To quantify the
severity of dementia symptoms the FTD modified Clinical
Dementia Rating Scale Sum of Boxes (FTD-CDR-SOB)
(Knopman et al., 2008) score was used. Additionally age,
education, disease duration and the occurrence of a positive
family history were assessed.
MRI Acquisition
All patients and controls underwent whole-brain T1-weighted
MRI on 3T scanners, and on 1.5T scanners, where 3T scanning
was not available. An array head coil with a minimum of 8
channels was used. 3D-MPRAGE sequences were acquired in
sagittal orientation with 1 mm x 1 mm in-plane resolution, slice
thickness 1 mm, and TR/TE = 2300/2.03 ms.
MRI Data Processing and Volumetric
Analysis
After pseudonymization and conversion from DICOM to
ANALYZE 7.5 format the 3D T1-weighted images were processed
by a fully automated and observer-independent method of
atlas- and mask-based MRI volumetry using the Statistical
Parametric Mapping 12 software (Wellcome Trust Centre
for Neuroimaging, London, United Kingdom)1. The method
has been described in detail elsewhere (Huppertz et al.,
2010, 2016; Opfer et al., 2016) and was already applied
to neurodegenerative diseases in various cross-sectional and
longitudinal studies (Kassubek et al., 2011; Frings et al., 2012,
2014; Höglinger et al., 2014; Huppertz et al., 2016; Schönecker
et al., 2016). In short, each T1 image was normalized to
Montreal Neurological Institute (MNI) template space using
diffeomorphic anatomical registration through exponentiated Lie
algebra (DARTEL) (Ashburner, 2007) and segmented into gray
1www.fil.ion.ucl.ac.uk/spm
matter, white matter, and cerebrospinal fluid components using
the ‘unified segmentation’ algorithm of Statistical Parametric
Mapping 12 with default parameters. The DARTEL algorithm
is a highly elastic registration method resulting in a more
precise registration of the individual brain to MNI space than
the normalization methods in previous SPM versions, thereby
also improving the adaptation to the space of the atlases used
in the further post-processing. The volumes of specific brain
structures and compartments were calculated by voxel-by-voxel
multiplication and subsequent integration of normalized and
modulated component images (gray matter, white matter or
cerebrospinal fluid) with predefined masks in the same space.
These masks are derived from different probabilistic brain atlases,
such as the LONI Probabilistic Brain Atlas (LPBA40) provided
by the Laboratory of Neuroimaging (LONI) at the University
of California, Los Angeles, United States2 (Shattuck et al., 2008)
and the probabilistic thalamic connectivity atlas provided by the
Nuffield Department of Clinical Neurosciences at the University
of Oxford, United Kingdom (Oxford Thalamic Connectivity
Atlas; OTH)3 (Behrens et al., 2003). Target structures were
chosen a priori for analysis of group differences in volume
(13 in total, see Table 2). As our study aimed to determine
the amount of thalamic and cerebellar atrophy of C9orf72
mutation carriers compared to sporadic patients and HC,
we included as regions of interest cerebellum, cerebellar
vermis plane and pons as derived from structures and further
parcellations in the LPBA40 atlas (Huppertz et al., 2016)
and in addition all structures of the OTH atlas, i.e., overall
thalamic volume as well as the primary motor, sensory, posterior
parietal, occipital, temporal and prefrontal subregion of the
thalamus that are connected to the corresponding cortical zone.
Furthermore, since frontotemporal cortex shows pronounced
atrophy in C9orf72 mutation carriers as well as in sporadic
patients the frontal and temporal cortex as derived from
the integration of single gyri of the LPBA40 atlas (Huppertz
et al., 2010) have been included as regions of interest as
well.
Statistical Analysis
Data were analyzed using SPSS23. Non-dichotomized mean
scores of demographic and neuropsychological data were
compared across the three groups (C9orf72 mutation carriers,
sporadic patients and HC) via Kruskal–Wallis test and Mann–
Whitney test. Chi-square analysis was used to check for
significant differences in gender and family history across all
groups. Standard statistical significance level was set at p< 0.05.
For each region of interest the individual volume at clinic
presentation was determined in ml. For comparison, the
measured volumes were corrected by individual intracranial
volume and standardized to the mean intracranial volume
of healthy controls.
For group comparisons of volumetric data, a Kruskal–Wallis
test was performed. Significance levels for the Kruskal–Wallis test
were adjusted according to Bonferroni correction (p < 0.0038).
2http://www.loni.usc.edu/atlases/
3http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/Atlases
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TABLE 1 | Demographics and neuropsychological measures of the study sample.
C9orf72 Sporadic HC C9orf72 vs. HC C9orf72 vs. sporadic sporadic vs. HC
N 13 45 19
Gender (M/F) 8/5 26/19 12/7 n.s. n.s. n.s.
Positive family history (Y/N) 8/5 12/33 1/18 + + n.s.
Age 64.1 (8.5) 62.8 (9.4) 65.9 (10.1) n.s. n.s. n.s.
Education 12.8 (2.7) 13.2 (3.3) 13.7 (3.1) n.s. n.s. n.s.
Disease duration 2.5 (3.5) 3.2 (3.7) n.s.
MMSE 25.8 (3.1) 25.6 (4.1) 29.0 (0.9) + n.s. +
FTLD-CDR-SOB 3.7 (1.0) 6.3 (2.9) 0.4 (0.6) + n.s. +
n.s., not significant; +p < 0.05.
TABLE 2 | Anatomical structures selected for volumetric analysis per group mean and SD (in ml), and pairwise post hoc Bonferroni test results.
Dependent variable C9orf72 Sporadic HC C9orf72 vs. HC C9orf72 vs. sporadic Sporadic vs. HC
Frontal 246.90 (26.96) 265.37 (33.10) 296.54 (15.82) + n.s. +
Temporal 158.31 (11.97) 164.44 (18.78) 181.70 (14.08) + n.s. +
Cerebellum 109.46 (9.82) 109.44 (11.43) 113.33 (10.24) n.s. n.s. n.s.
Cerebellar vermis plane 949.72 (101.54) 973.68 (96.92) 1020.74 (86.26) n.s. n.s. n.s.
Pons 15.30 (1.40) 15.23 (1.76) 15.25 (1.36) n.s. n.s. n.s.
Thalamic regions
Thalamus all 15.70 (1.49) 17.62 (1.62) 19.09 (1.50) + + +
Primary motor 0.97 (0.08) 1.03 (0.07) 1.06 (0.08) n.s. n.s. n.s.
Sensory 1.11 (0.09) 1.18 (0.09) 1.23 (0.09) + + n.s.
Premotor 1.70 (0.15) 1.84 (0.14) 1.92 (0.14) + + n.s.
Posterior parietal 3.09 (0.27) 3.35 (0.26) 3.50 (0.25) + + n.s.
Occipital 1.41 (0.13) 1.62 (0.18) 1.77 (0.16) + + +
Temporal 2.91 (0.29) 3.45 (0.48) 3.92 (0.43) + + +
Prefrontal 4.52 (0.37) 5.14 (0.51) 5.70 (0.46) + + +
n.s., not significant; +p < 0.05, corrected for multiple comparisons.
Results of post-hoc tests were regarded significant if they survived
an additional Bonferroni correction for multiple pairwise group
comparisons. Spearman’s test was used to explore significant
correlations between volumetric data and neuropsychological
variables. Significance level was adjusted according to Bonferroni
correction (p< 0.0038) as well.
Furthermore, to assess laterality of overall thalamic volume
and thalamic subregions a laterality index (LI) defined as the
ratio [(left − right)/(left + right)] was calculated (Seghier, 2008;
Okada et al., 2016) for each study group. LIs can range from −1
to 1 with a positive LI indicating a leftward asymmetry. One-
sample Wilcoxon signed rank tests were calculated to evaluate
whether LIs were significantly different from zero. A Kruskal–
Wallis test was performed for group comparisons of LIs. As for
the volumetric analysis significance level was adjusted according
to Bonferroni correction (p< 0.00625) and an additional post hoc
Bonferroni correction was performed.
Parameters showing a significant difference between C9orf72
mutation carriers and sporadic patients in the former analyses,
i.e., overall thalamic volume and the volumes of the sensory,
premotor, parietal, occipital, temporal and prefrontal subregion
of the thalamus, the LI of the primary motor, sensory, premotor,
occipital and prefrontal subregion of the thalamus as well as
the neuropsychological parameters MMSE and FTD-CDR-SOB
were subjected to a forward stepwise binary logistic regression
to determine the best predictor of diagnosis. Furthermore, the
receiver operating characteristic (ROC) curve was created to
evaluate the utility of the model at distinguishing between
C9orf72 mutation carriers and sporadic patients.
RESULTS
Demographics and Cognitive Scores
Demographics and cognitive scores of the study sample can
be seen in Table 1. Participant groups did not differ in terms
of gender, age, education and disease duration. Patient groups
(C9orf72 mutation carriers and sporadic patients) performed
significantly worse at cognitive screening tests (MMSE and FTD-
CDR-SOB) compared to HC but did not differ significantly
from one another. C9orf72 mutation carriers had, as expected,
significantly more frequently a positive family history compared
to sporadic patients and HC (see Table 1).
Volumetric Analysis
Kruskal–Wallis test revealed significant differences of the
volumes of the frontal and temporal lobe, overall thalamic
volume (Figure 1) and the volumes of the sensory, premotor,
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FIGURE 1 | Volumes of frontal and temporal lobe, cerebellum and thalamus. ∗ Indicates significant differences.
posterior parietal, occipital, temporal and prefrontal subregion
of the thalamus (Figure 2). No significant differences could be
detected for the cerebellum, the cerebellar vermis plane and pons
as well as for the primary motor subregion of the thalamus
(Figures 1, 2).
Post hoc Bonferroni tests showed that sporadic patients
compared to HC had reduced volumes of the frontal and
temporal lobe as well as reduced volumes of overall thalamus
and the occipital, temporal and prefrontal subregion of the
thalamus (Figures 1, 2 and Table 2). Similarly, C9orf72 mutation
carriers had significantly smaller volumes of frontal and temporal
lobe as well as all investigated thalamic subregions apart from
the primary motor subregion (i.e., sensory, premotor, posterior
parietal, occipital, temporal and prefrontal subregion of the
thalamus) compared to HC. No significant differences of frontal
and temporal lobe volumes could be detected between C9orf72
mutation carriers and sporadic patients. However, although
sporadic patients were somewhat more advanced, both in disease
duration and in the FTD-CDR-SOB, C9orf72 mutation carriers
showed significantly smaller volumes of the sensory, premotor,
posterior parietal, occipital, temporal and prefrontal subregion of
the thalamus (Figure 2 and Table 2).
Correlation Analysis
Correlation analysis showed a significant positive/negative
correlation of MMSE/FTD-CDR-SOB with overall thalamic
volume (rs = 0.352, rs = −0.406), the volumes of the prefrontal
(rs = 0.368, rs = −0.453), temporal (rs = 0.377, rs = −0.423)
and occipital (rs = 0.367, rs = −0.385) subregion of the thalamus
as well as with frontal (rs = 0.392, rs = −0.607) and temporal
(rs = 0.364, rs =−0.391) lobe volume (Figure 3).
Laterality Indices
Laterality indices were investigated in this study as well. All
study groups showed positive LIs of the occipital, prefrontal, and
posterior parietal subregion of the thalamus and significantly
negative LIs of the primary motor, sensory, premotor and
temporal subregion of the thalamus. Overall thalamic volume
showed significantly positive LIs in sporadic patients and HC
but was not significantly different from zero in C9orf72 mutation
carriers.
Kruskal–Wallis test revealed significant group differences of
the LIs of overall thalamus and of the primary motor, sensory,
premotor, occipital and prefrontal subregion of the thalamus.
Only for the posterior parietal and the temporal subregion
of the thalamus, no significant group differences could be
detected. C9orf72 mutation carriers differed significantly from
sporadic patients in the aforementioned LIs. Furthermore LIs
of overall thalamus, sensory, premotor, occipital and prefrontal
subregion of the thalamus differed significantly between C9orf72
mutation carriers and HC. No significant differences of LIs
could be detected between sporadic patients and HC. For every
investigated thalamic subregion as well as for overall thalamus,
C9orf72 mutation carriers showed the lowest LIs (Table 3).
Binary Logistic Regression
Target volumes, LIs and neuropsychological variables that
showed a significant difference between C9orf72 mutation
carriers and sporadic patients were subjected to a forward
stepwise binary logistic regression to determine the best predictor
of diagnosis. The optimal logistic regression model using the
volume of the prefrontal subregion of the thalamus (B = −2.54)
and the LI of the occipital subregion of the thalamus (B =−24.81)
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FIGURE 2 | Volumes of thalamic subregions. ∗ Indicates significant differences.
FIGURE 3 | Linear correlation between volumetric data and neuropsychological variables. There is a significant negative/positive correlation of
FTD-CDR-SOB/MMSE with the volumes of the prefrontal, temporal and occipital subregion of the thalamus.
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TABLE 3 | Laterality indices of overall thalamus and thalamic subregions, and pairwise post hoc Bonferroni test results.
Dependent variable C9orf72 Sporadic HC C9orf72 vs. HC C9orf72 vs. sporadic Sporadic vs. HC
Overall thalamus 0.0061 0.0327 0.0349 + + n.s.
Primary motor −0.0956 −0.0687 −0.0722 n.s. + n.s.
Sensory −0.0731 −0.0494 −0.0503 + + n.s.
Premotor −0.0795 −0.0531 −0.0548 + + n.s.
Posterior parietal 0.0360 0.0576 0.0525 n.s. n.s. n.s.
Occipital 0.2373 0.2698 0.2814 + + n.s.
Temporal −0.0713 −0.0448 −0.0419 n.s. n.s. n.s.
Prefrontal 0.0366 0.0632 0.0690 + + n.s.
n.s., not significant; +p < 0.05, corrected for multiple comparisons.
as predictor variables (p< 0.05; Nagelkerke’s R2 = 0.441) resulted
in an area under the curve (AUC) of 0.88 (95% CI: 0.80 –
0.97). The highest combination of sensitivity and specificity was
acquired with a sensitivity of 1.00 and a specificity of 0.69 at a
predicted probability cutoff of 0.14.
A logistic regression model using only overall thalamic
volume as predictor variable (B = −0.82, p < 0.05; Nagelkerke’s
R2 = 0.327) still resulted in an AUC of 0.82 (95% CI: 0.70 –
0.94). The highest combination of sensitivity and specificity was
acquired with a sensitivity of 0.69 and a specificity of 0.84 at a
predicted probability cutoff of 0.33. The ROC curves are shown
in Figure 4.
DISCUSSION
Neuropathological data show that DPR protein aggregates are
abundant in the thalamus (Schludi et al., 2015). This is in
accordance with previous reports of significant thalamic atrophy
in C9orf72 mutation carriers (Sha et al., 2012; Mahoney et al.,
2012; Irwin et al., 2013). Furthermore, an early affection of
the thalamus in presymptomatic C9orf72 mutation carriers has
been shown (Rohrer et al., 2015). Here we show a significant
volume reduction of certain thalamic subregions of symptomatic
C9orf72 mutation carriers compared to sporadic patients and
HC and reveals overall thalamic volume to be a useful predictor
of C9orf72 mutation carrier status. The negative correlation of
thalamic volume and clinical parameters highlights the important
role of the thalamus in the pathogenesis of C9orf72 associated
clinical pictures of FTD and ALS.
C9orf72 mutation carriers present more frequently with
psychotic symptoms and show more severe memory impairment
than sporadic patients (Boeve et al., 2012; Snowden et al., 2015).
In our study cohort, disease severity measured by MMSE and
FTD-CDR-SOB was not only correlated with the volumes of
the frontal and temporal lobes but also with overall thalamic
volume and the volumes of the prefrontal, temporal and occipital
subregion of the thalamus, illustrating their clinical relevance.
These subregions furthermore showed the most striking
volumetric differences between C9orf72 mutation carriers and
sporadic patients. The occipital subregion includes lateral
geniculate nucleus and parts of the inferior pulvinar, temporal
subregion includes parts of the mediodorsal nucleus (MDN) and
FIGURE 4 | Receiver operating characteristic curves for logistic regression
models of C9orf72 mutation carriers versus sporadic patients. Model 1: Using
the prefrontal subregion of the thalamus and the LI of the occipital subregion
of the thalamus as predictor variables results in an AUC of 0.88. Model 2:
Using only overall thalamic volume as predictor variable still results in an AUC
of 0.82.
the medial and inferior pulvinar and the prefrontal subregion
includes some of MDN, ventral anterior nucleus and anterodorsal
and anteromedial nucleus (Behrens et al., 2003; Johansen-Berg
et al., 2005).
The “Salience Network (SN)” (Seeley et al., 2007) is an intrinsic
connectivity network that is activated in response to emotionally
significant stimuli and contributes to complex brain functions
like guidance of behavioral responses, production of subjective
feelings and initiation of cognitive control (Menon and Uddin,
2010; Medford and Critchley, 2010). The SN is anchored in the
dorsal anterior cingulate and anterior insula but also includes
various subcortical structures. Comparable SN disruption despite
contrasting atrophy patterns in C9orf72 mutation carriers and
sporadic patients has been described (Lee et al., 2014). Atrophy
of the medial pulvinar nucleus that has prominent reciprocal
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connections to major hubs of the SN (Romanski et al., 1997)
could only be detected in C9orf72 mutation carriers. As medial
pulvinar nucleus atrophy predicted reduced SN connectivity,
a strategic atrophy of the medial pulvinar nucleus has been
proposed to contribute to SN disruption in C9orf72 mutation
carriers (Lee et al., 2014). We therefore hypothesize that especially
atrophy of the medial pulvinar nucleus may have led to the
detected volume reduction of the temporal subregion of the
thalamus of C9orf72 mutation carriers in our study cohort.
Another thalamic node that is part of the SN is the MDN.
Studies detected significant atrophy of MDN in early stages of
FTD (Seeley et al., 2008). MDN is believed to be involved in
the pathogenesis of schizophrenia (Young et al., 2000; Alelú-
Paz and Giménez-Amaya, 2008) and has been shown to play an
important role in working memory and episodic memory (Gaffan
and Parker, 2000; Watanabe and Funahashi, 2012; Mitchell
and Chakraborty, 2013). It is involved in memory formation
and influences emotional connotations also via extralemniscal
pathways, e.g., connecting to the amygdala. For ALS a more
frequent bulbar onset in mutation carriers is discussed. With
view to FTD, mutation carriers may present with more psychosis
displaying delusions and hallucinations and/or catatonic features.
Also, late-onset dementia and depressive syndromes with
cognitive impairments were reported (Ducharme et al., 2017).
We hypothesize that MDN atrophy is reflected by the volume
reduction of the temporal and prefrontal subregion of the
thalamus of C9orf72 mutation carriers and that MDN atrophy
leads to a disruption of SN and thereby contributes to the
distinct clinical characteristics of mutation and non-mutations
carriers.
Several studies have reported greater occipital (Boxer et al.,
2011; Khan et al., 2012; Whitwell et al., 2012) and parietal
(Sha et al., 2012; Whitwell et al., 2012) volume loss of
C9orf72 mutation carriers compared to sporadic patients.
The detected volume loss of the occipital, posterior parietal
and sensory subregion of the thalamus of C9orf72 mutation
carriers may therefore be due to a common degeneration
of functionally connected regions. The fact that the atrophy
pattern in our C9orf72 mutation carrier study group goes
beyond the expected atrophy in the frontal and temporal
subregion of the thalamus is an indicator that atrophy in
mutation carriers may exceed the SN and is in keeping with
the described cortical pattern of atrophy detected in mutation
carriers that also goes beyond the sporadic FTD-associated
atrophy pattern.
In a recent volumetric MRI study, a classification accuracy
of 93% could be obtained to discriminate between C9orf72
mutation carriers, MAPT and GRN mutation carriers and
sporadic patients by using 26 regional volume and asymmetry
scores (Whitwell et al., 2012). A more conservative model
requiring 14 variables was able to classify 74% of patients
correctly. In contrast to the aforementioned study, we compared
only C9orf72 mutation carriers and sporadic patients. As group
sizes differed in our study cohort, classification accuracy cannot
directly be compared. Furthermore, as multicollinearity was
present in our data, results of binary logistic regression have
to be interpreted with caution. However, multicollinearity does
not bias the result of logistic regression, but only affects
calculations regarding individual predictor variables (Midi et al.,
2010). The optimal logistic regression model resulted in an
AUC of 0.88 while a logistic regression model using only
overall thalamic volume as predictor variable still resulted in an
AUC of 0.82. Both AUCs correspond to very good diagnostic
accuracy (Šimundic´, 2008). Our data therefore provide evidence
of a combination of the volume of the prefrontal subregion
and the LI of the occipital subregion of the thalamus and
overall thalamic volume respectively to be of high predictive
value in identifying C9orf72 mutation carriers. MRI volumetry,
especially of subcortical regions of interest, may therefore help
to differentiate between C9orf72 mutation carriers and sporadic
patients, regardless of the presence of a positive family history.
This is particularly useful since prediction of mutation status is
extremely difficult based on clinical features alone. Nonetheless,
the addition of clinical information like prominent psychosis or
memory impairment (Boeve et al., 2012; Snowden et al., 2015),
co-occurring FTD and ALS symptoms (DeJesus-Hernandez
et al., 2011) and a positive family history may further improve
prediction.
As in previous studies examining thalamic asymmetries in
control subjects, we were able to detect left greater than right
asymmetry in our HC (Flaum et al., 1995; Okada et al., 2016).
Leftward asymmetry could also be detected in sporadic patients.
Mainly the posterior parietal, occipital and prefrontal subregion
of the thalamus seem to contribute to the detected overall
leftward asymmetry, whereas the primary motor, premotor,
sensory and temporal subregion of the thalamus display a
rightward asymmetry. In contrast, although each thalamic
subregion showed either rightward or leftward asymmetry, no
significant overall thalamic asymmetry could be detected in
C9orf72 mutation carriers. This is consistent with the symmetric
cortical atrophy pattern detected in C9orf72 mutation carriers
(Mahoney et al., 2012; Whitwell et al., 2012).
Although abundant DPR pathology within granule cell layer
of the cerebellum seems to be a consistent finding in C9orf72
mutation carriers (Al-Sarraj et al., 2011; Irwin et al., 2013) and
a number of studies have reported more prominent cerebellar
atrophy in C9orf72 mutation carriers compared to sporadic
patients (Mahoney et al., 2012; Whitwell et al., 2012; Irwin et al.,
2013), we were not able to detect significant group differences
with respect to cerebellar volume. In a recent study, focal atrophy
localized to lobule VIIa-Crus I in the superior-posterior region
of the cerebellum could be detected in C9orf72 mutation carriers
compared to HC (Bocchetta et al., 2016). As this area is connected
via the thalamus to the prefrontal cortex (Krienen and Buckner,
2009; Stoodley and Schmahmann, 2010) and therefore with
the SN (Caulfield et al., 2016) and is associated with goal-
directed behaviors, its involvement in C9orf72-associated FTD
and ALS seems plausible. Perhaps an investigation of cerebellar
subregions would have revealed atrophy clusters specific for
C9orf72 mutation carriers.
A limitation of the current study that needs to be considered
is the small number of C9orf72 mutation carriers enrolled
(N = 13) which rendered subdividing C9orf72 mutation carriers
in FTD, FTD/ALS and ALS patients impossible. Further studies
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of larger cohorts subdividing the different C9orf72 mutation
carrier phenotypes are necessary. Furthermore multi-scanner
data-sets and scans performed on 3T scanners and on 1.5T
scanners have been pooled in the analyses. However multi-site
studies offer a good possibility to investigate rare disorders like
neurodegenerative diseases caused by c9orf72 mutation carrier
status. Another limitation of our study was the absence of a
neuropathological confirmation of our sporadic patient study
group which leaves the possibility that a percentage of cases had a
mismatch of clinical diagnosis and underlying pathology.
Keeping these limitations in mind, our findings reveal a
combination of the volume of the prefrontal subregion and the
LI of the occipital subregion of the thalamus and overall thalamic
volume respectively to be useful predictors of mutation carrier
status. We furthermore demonstrated that the thalamic atrophy
pattern in C9orf72 mutation carriers goes beyond hubs of the
SN and is in good agreement with the cortical atrophy pattern
detected in C9orf72 mutation carriers, indicating a retrograde
degeneration of functionally connected regions.
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